Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23380139 | 0.85 | KDM4E (0.47) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL25796607 | 0.79 | CNR2 (0.53) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL859427 | 0.79 | KDM4E (0.49) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL29342011 | 0.78 | ALDH1A1 (0.49) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL3059091 | 0.78 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL858867 | 0.78 | NPC1 (0.67) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL12764246 | 0.75 | NPC1 (0.48) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL21000856 | 0.74 | GAA (0.50) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL12725093 | 0.74 | ALDH1A1 (0.63) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 | |
| SCHEMBL25330916 | 0.72 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2HTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384099-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-20210147446-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147446-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | FGFR1, FGFR3, FGFR2 | KDM4E 964/4885SMN1; SMN2 2331/4885HTT 1848/4885 |
| US-11384099-B2 | Pyrazolopyridinone compounds | FGFR1, FGFR3, FGFR2 | KDM4E 964/4885SMN1; SMN2 2331/4885HTT 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.